Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study
@seer_bio @mkrdonovan #proteomics #biomarkerdiscovery #proteoform
It’s a thrilling time to be in proteomics. Today we discuss a recent paper in PLOS One demonstrating how new technology has revealed a novel biomarker for non-small cell lung cancer previously undetected by other methods. The paper could be a model for new proteomics research going forward. Our guests are Margaret Donovan, Product Marketing Manager, and Asim Siddiqui, Senior VP of Research, both at proteomics company, Seer. “Historically the way in which we’ve been able to analyze the proteome has essentially meant you’re making trade-offs.
Don't miss tomorrow's #Proteoform Thursday: Dr. Gloria Sheynkman will present a "Systems Biology Approach to Discover the Proteoform Drivers of Disease"
She is an all-star of #proteogenomics and #proteomics!
The post-genomic era is marked by the development of technologies which have revealed the astonishing molecular diversity of gene products. Diverse protein forms, or “proteoforms”, can arise from post-transcriptional mechanisms such as alternative splicing and/or post-translational mechanisms such as phosphorylation. The existence of so many distinct proteoforms being produced from the same genetic locus prompts revisiting of the traditional notion of the “gene”. It motivates the urgent need to enumerate all healthy and disease-associated proteoforms in human and to assess their functional significance. In this seminar, Dr. Sheynkman will present approaches for 1) enhanced detection of protein isoforms, using a recently developed “long read proteogenomics” approach, 2) an integrative systems genetics approach for discovering protein isoform drivers of disease, and 3) computational predictive and interactomics approaches to dissect the mechanism by which protein isoforms drive phenotypic changes. The lab aims to be a collaborative link in developing these ideas across fields to support the vision of the Human Proteoform Project. About Gloria Sheynkman Dr. Sheynkman received her BS in Biochemistry from the University of Notre Dame. She has industry experience from working at Gilead Sciences in the Analytical Development department. She then received her PhD from the University of Wisconsin-Madison where she developed integrative proteogenomics methods to discover human proteomic variation. Dr. Sheynkman was a postdoctoral fellow at the Dana-Farber Cancer Institute and Harvard Medical School, where she developed high-throughput functional proteomics approaches to characterize normal and disease protein isoforms. Most recently, she was recruited to the University of Virginia in the summer of 2020 and is an Assistant Professor with a primary appointment in The Department of Molecular Physiology and Biological Physics.
PastelBio
Dave Tabb
Mendelspod
Dave Tabb